Relay Therapeutics Inc’s filing revealed that its insider Rahmer Peter unloaded Company’s shares for reported $32217.0 on Apr 30 ’25. In the deal valued at $3.00 per share,10,739 shares were sold. As a result of this transaction, Rahmer Peter now holds 390,081 shares worth roughly $1.31 million.
Then, Rahmer Peter sold 1,364 shares, generating $4,324 in total proceeds. Upon selling the shares at $3.17, the insider now owns 400,820 shares.
Before that, Catinazzo Thomas sold 12,943 shares. Relay Therapeutics Inc shares valued at $38,829 were divested by the Chief Financial Officer at a price of $3.00 per share. As a result of the transaction, Catinazzo Thomas now holds 355,376 shares, worth roughly $1.19 million.
Wells Fargo initiated its Relay Therapeutics Inc [RLAY] rating to an Equal weight in a research note published on April 17, 2025; the price target was $4. A number of analysts have revised their coverage, including Jefferies’s analysts, who increased its forecast for the stock in early September from “a Hold” to “a Buy”. Oppenheimer revised its rating on September 10, 2024. It rated RLAY as “a Perform” which previously was an “an Outperform”.
Price Performance Review of RLAY
On Friday, Relay Therapeutics Inc [NASDAQ:RLAY] saw its stock unchanged to $3.36. Over the last five days, the stock has gained 5.66%. Relay Therapeutics Inc shares have fallen nearly -18.45% since the year began. Nevertheless, the stocks have fallen -54.22% over the past one year.
Levels Of Support And Resistance For RLAY Stock
How much short interest is there in Relay Therapeutics Inc?
A steep rise in short interest was recorded in Relay Therapeutics Inc stocks on 2025-05-15, growing by 4.8 million shares to a total of 23.16 million shares. Yahoo Finance data shows the prior-month short interest on 2025-04-15 was 18.36 million shares. There was a rise of 20.7%, which implies that there is a positive sentiment for the stock.
